INCORTA
8.6.2021 17:14:04 CEST | Business Wire | Press release
Incorta , the Direct Data Platform™, today announced a multi-year partnership with MDSap , a sub-holding of Midis Group, a global leader in redistributing and reselling, to expand its go-to-market in the Middle East, Turkey, and Eastern Europe and address the region’s growing need for modern analytics and business intelligence. The partnership will provide MDSap’s 400 global enterprise customers with a fast and scalable data analytics solution, bringing Incorta’s Direct Data Platform to key regions such as the Middle East, North Africa, Turkey and Eastern Europe.
The COVID-19 pandemic spurred a rapid increase in the need for advanced technology, and Incorta’s presence in the Middle East is expected to grow by more than 100% this year – a market valued at $11 billion in 2020 and expected to reach $28 billion by 2026. The partnership will help replace outdated, legacy solutions, bringing modern data analytics to new and existing customers at unprecedented speed and scale.
“We’re thrilled to partner with Incorta to bring their state-of-the-art data analytics solution to our enterprise customers,” said Tony Achkar, group managing director of MDSap. “As the Middle East, Turkey and Eastern Europe regions continue to experience rapid digitization, our customers need a modern solution to help them keep up with today’s pace of business. Incorta is allowing them to analyze their data at a level of speed and scale they’ve never seen before.”
As SAP’s gold partner, MDSap leverages SAP technology and other solution providers to help businesses run smoothly and efficiently. Making smart, data-informed decisions is a key part of operating a business, as MDSap customers require the ability to quickly analyze, ingest and then act on their data in order to gain crucial insights about their business. Incorta’s Direct Data Platform will enable users to analyze massive sets of data at lightning speed, allowing them to maximize the full value of their data.
“The Middle East presents exciting opportunities for digital transformation and growth, especially in the data analytics market,” said Incorta CEO Scott Jones. “We are proud to be partnering with MDSap to help more companies in the region innovate and thrive with tools for making the most of their business data.”
The Incorta and MDSap integration is available now.
For more information, visit https://www.incorta.com/partners/mdsap .
About Incorta
Incorta is the only unified data analytics platform powered by Direct Data Mapping™. Purpose-built to help companies stay ahead of the accelerating rate, volume, and complexity of modern enterprise data, the platform delivers unmatched speed and visibility. Incorta is built with open standards and integrates with cloud-friendly tools and platforms, making it easy to consolidate data in the cloud and extract meaningful insights. By making any data source continuously available for analytics, the platform helps business leaders, business teams, and data scientists make more accurate, timely and transparent decisions with faster access to richer data sets. Backed by GV (formerly Google Ventures), Kleiner Perkins, M12 (formerly Microsoft Ventures), Telstra Ventures and Sorenson Capital, Incorta powers analytics for some of the most valuable brands in the world, including Broadcom, Credit Suisse and Shutterfly. To learn more and try it for yourself, visit www.incorta.com .
About MDSap
MDSap, a gold partner of SAP and expert in SAP’s banking solutions, has over 25 years of in-depth experiences helping customers manage, integrate, analyse and mobilize business mission critical data across the enterprise. The company has an exceptional track record providing turnkey IT solutions across the Middle East, Turkey & Central Eastern Europe to over 400 enterprise customers and government entities. MDSap is part of the Midis Group and is a member of EPM International and currently operates 10 offices across the Middle East, Turkey and Central Eastern Europe.
For more information, visit https://www.mdsaptech.com/en/ .
About Midis Group
With more than 5,000 professionals, representing the top 100 global IT vendors, and a solid 50-year track record of performance and reliability, the Midis Group is an international organization of over 170 companies across Europe, the Middle East & Africa. The group is known for its advanced offering of managed IT services and consultancy, system integration, cloud and data center capabilities and infrastructure, software and hardware solutions, as well as technology distribution and retail. It was named in 2006 as one of the World Economic Forum’s initial 100 Global Growth Companies. The group focuses on providing the best in services, with integrity, to vendors, partners, and customers across the destinations it serves. For more information, visit: www.midisgroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005870/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom